Pharmison Valentes Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 30-07-2024
- Paid Up Capital ₹ 10.00 K
as on 30-07-2024
- Company Age 5 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 23.70%
(FY 2023)
- Profit 239.04%
(FY 2023)
- Ebitda 233.16%
(FY 2023)
- Net Worth 15.94%
(FY 2023)
- Total Assets -44.10%
(FY 2023)
About Pharmison Valentes Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 10.00 K , as per Ministry of Corporate Affairs (MCA) records.
Partha Putatunda, Alap Putatunda, Bipradas Bhaumik, and One other member serve as directors at the Company.
- CIN/LLPIN
U24304WB2019PTC232164
- Company No.
232164
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 May 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Krishnanagar, West Bengal, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Pharmison Valentes Pharma?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Partha Putatunda  | Director | 28-May-2019 | Current |
| Alap Putatunda | Director | 28-May-2019 | Current |
| Bipradas Bhaumik | Director | 12-Feb-2021 | Current |
| Sanglap Putatunda | Director | 21-Jun-2024 | Current |
Financial Performance of Pharmison Valentes Pharma.
Pharmison Valentes Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 23.7% increase. The company also saw a substantial improvement in profitability, with a 239.04% increase in profit. The company's net worth Soared by an impressive increase of 15.94%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Pharmison Valentes Pharma?
In 2023, Pharmison Valentes Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Saytech Online Services Private LimitedActive 3 years 6 months
Alap Putatunda and Bipradas Bhaumik are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Pharmison Valentes Pharma?
Pharmison Valentes Pharma has a workforce of 12 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Pharmison Valentes Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pharmison Valentes Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
